Analyst: Novo Nordisk's price reductions challenge complex healthcare system
A Sydbank analyst thinks the Danish drugmaker’s lowering of its insulin list prices is ”almost a reckoning with the US healthcare system.”
by marketwire, translated by daniel pedersen
There are numerous reasons why Danish drugmaker Novo Nordisk and some of its pharmaceutical competitors have chosen to lower list prices of certain insulin products substantially.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
